Loading...
Chimeric Therapeutics Limited
CHM.AX•ASX
Healthcare
Biotechnology
A$0.003
A$0.00(0.00%)
Chimeric Therapeutics Limited (CHM.AX) Financial Performance & Income Statement Overview
Review Chimeric Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
65.52%
↑ 65.52%
Operating Income Growth
58.25%
↑ 58.25%
Net Income Growth
51.65%
↑ 51.65%
Operating Cash Flow Growth
53.80%
↑ 53.80%
Operating Margin
-373.03%
↓ 373.03%
Gross Margin
87.32%
↑ 87.32%
Net Profit Margin
-469.54%
↓ 469.54%
ROE
-424.06%
↓ 424.06%
ROIC
-167.63%
↓ 167.63%
Chimeric Therapeutics Limited (CHM.AX) Income Statement & Financial Overview
Review Chimeric Therapeutics Limited's (CHM.AX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | -$1.76M | $5.49M | $705815.00 | $705815.00 |
| Cost of Revenue | $481484.00 | $486775.00 | $0.00 | $0.00 |
| Gross Profit | -$2.24M | $5.00M | $705815.00 | $705815.00 |
| Gross Profit Ratio | $1.27 | $0.91 | $1.00 | $1.00 |
| R&D Expenses | $6.81M | $4.34M | $7.21M | $3.60M |
| SG&A Expenses | $4.13M | $4.38M | $7.62M | $3.81M |
| Operating Expenses | $11.02M | $8.73M | $14.83M | $7.42M |
| Total Costs & Expenses | $11.51M | $9.21M | $14.83M | $7.42M |
| Interest Income | $72885.00 | $48430.00 | $11976.00 | $375784.00 |
| Interest Expense | $80.00 | $331731.00 | $763543.00 | $0.00 |
| Depreciation & Amortization | $259677.00 | $486775.00 | $243390.00 | $243390.00 |
| EBITDA | -$12.33M | -$2.65M | -$14.83M | -$6.42M |
| EBITDA Ratio | $7.02 | -$1.59 | -$9.10 | -$9.10 |
| Operating Income | -$11.51M | -$9.21M | -$14.83M | -$6.67M |
| Operating Income Ratio | $6.55 | -$1.68 | -$21.010 | -$9.45 |
| Other Income/Expenses (Net) | -$1.30M | $5.74M | -$8.88M | -$375783.00 |
| Income Before Tax | -$12.81M | -$3.47M | -$15.59M | -$7.09M |
| Income Before Tax Ratio | $7.29 | -$0.63 | -$22.09 | -$10.05 |
| Income Tax Expense | $2.16M | -$5.91M | -$1.42M | $5771.00 |
| Net Income | -$14.97M | $2.44M | -$14.17M | -$7.08M |
| Net Income Ratio | $8.53 | $0.45 | -$20.08 | -$10.04 |
| EPS | -$0.02 | $0.004 | -$0.03 | -$0.02 |
| Diluted EPS | -$0.02 | $0.004 | -$0.03 | -$0.02 |
| Weighted Avg Shares Outstanding | $680.63M | $557.64M | $438.40M | $438.92M |
| Weighted Avg Shares Outstanding (Diluted) | $680.63M | $557.64M | $438.40M | $438.90M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan